Desire starts in the brain. Let’s wake it up.

PT-141 is bremelanotide, a peptide that acts on melanocortin receptors in the brain involved in sexual desire and arousal. The FDA-approved version is an injection for premenopausal women with acquired, generalized HSDD. Rebody’s troche and nasal spray are compounded, needle-free formats.

Blood-flow medications act on the body’s physical response. PT-141 works through melanocortin signaling in the brain, a pathway involved in the desire and arousal that come before the physical response.

Rebody offers one 10 mg/mL nasal spray in a refrigerated 5 mL bottle. The prescription label supplies the exact metered-dose directions.

Use the number of sprays on your prescription label. It will list the pump output, sprays per dose, nostril directions, timing, and maximum frequency.

The phase 3 trials studied a 1.75 mg injection for 24 weeks. A separate crossover study tested one 20 mg intranasal dose in 18 premenopausal women. Rebody’s nasal spray comes in a 5 mL bottle with prescription-specific pump directions.

People with uncontrolled high blood pressure or known cardiovascular disease should not use the FDA-approved injection. Its label also covers temporary blood-pressure increases, heart-rate decreases, nausea, focal hyperpigmentation, pregnancy, and drug interactions.

Yes. Complete the private online intake for clinician review. If prescribed, your label will include the exact directions, strength, storage, and refill timing.